

VIZYLAC JUNIOR

For the use of a Registered Medical Practitioner or a Hospital or a Laboratory only

Abbreviated Prescribing information for VIZYLAC JUNIOR (Bacillus Clausii Spores Suspension) [Please refer the complete prescribing information available at www.torrentpharma.com]

PHARMACOLOGICAL PROPERTIES: VIZYLAC JUNIOR contains the active substance Bacillus Clausii Spores Suspension. VIZYLAC JUNIOR is used for the alteration of intestinal bacterial flora. VIZYLAC JUNIOR contains spores of polyantibiotic - resistant strains of Bacillus clausii (19T, 21C, 28S & 30R). B. clausii strains release antimicrobial substances in the medium. The release of these antimicrobial substances was observed during stationary growth phase and coincided with sporulation. These substances were active against Gram-positive bacteria, in particular against Staphylococcus aureus, Enterococcus faecium, and Clostridium difficile.

INDICATION: It is indicated for alteration of intestinal bacterial flora.

DOSAGE AND ADMINISTRATION: Oral suspension, *Method of administration:* Shake the bottle before use. To open the bottle, break by twisting and remove the top of the cap. Take the contents directly or dilute in water or other drinks (e.g. milk, beverages). Once open, the drug should be taken within a short time to avoid contaminating the suspension.

CONTRAINDICATION: None known

WARNINGS & PRECAUTIONS: Do not use if hypersensitive to the active ingredient or excipients. During treatment with antibiotics, it is recommended that Bacillus clausii spores suspension be administered during the interval between antibiotic administrations. *It's important to know that:* The possible presence of corpuscles visible in the mini bottles of Bacillus clausii spores suspension is due to aggregates of Bacillus clausii spores and does not, therefore, indicate that the product has undergone any changes.

DRUG INTERACTIONS: Interactions with other drugs have not been observed.

ADVERSE REACTIONS: None known

MARKETED BY:



TORRENT PHARMACEUTICALS LTD.

IN/ VIZYLAC JUNIOR / MAY-22/01/ABPI
(Additional information is available on request)